| 1207113-88-9 Basic information More.. |
Product Name: | CCG-100602 | Synonyms: | CCG-100602;1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide;3-Piperidinecarboxamide, 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-;CCG-100602 >=98% (HPLC);CCG 100602,Inhibitor,transcription,inhibit,serum,myocardin,nuclear,SRF,CCG100602,MRTF-A,CCG-100602,Ras,localization | CAS: | 1207113-88-9 | MF: | C21H17ClF6N2O2 | MW: | 478.82 | EINECS: | | Mol File: | 1207113-88-9.mol | |
Use
The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding. CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC50 value of 9.8 μM. At 100 μM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 μM.[Cayman Chemical]
|
1207113-88-9
Recommend Suppliers |
|